1
|
Ubogu EE, Conner JA, Wang Y, Yadav D, Saunders TL. Development of a major histocompatibility complex class II conditional knockout mouse to study cell-specific and time-dependent adaptive immune responses in peripheral nerves. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.07.24.550421. [PMID: 37546875 PMCID: PMC10402085 DOI: 10.1101/2023.07.24.550421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/08/2023]
Abstract
Introduction Major histocompatibility complex (MHC) class II professional antigen presenting cell-naïve CD4+ T cell interactions via the T-cell receptor complex are necessary for adaptive immunity. MHC class II upregulation in multiple cell types occurs in human autoimmune polyneuropathy patient biopsies, necessitating studies to ascertain cellular signaling pathways required for tissue-specific autoimmunity. Methods Cryopreserved Guillain-Barré syndrome (GBS) patient sural nerve biopsies and sciatic nerves from the severe murine experimental autoimmune neuritis (sm-EAN) GBS model were studied. Cultured conditional ready MHC Class II antigen A-alpha chain (H2-Aa) embryonic stem cells were used to generate H2-Aa flox/+ C57BL/6 mice. Mice were backcrossed and intercrossed to the SJL background to generate H2-Aa flox/flox SJL mice, bred with hemizygous Tamoxifen-inducible von Willebrand factor Cre recombinase (vWF-iCre/+) SJL mice to generate H2-Aa flox/flox ; vWF-iCre/+ to study microvascular endothelial cell adaptive immune responses. Sm-EAN was induced in adult female SJL Tamoxifen-treated H2-Aa flox/flox ; vWF-iCre/+ mice and H2-Aa flox/flox ; +/+ littermate controls. Neurobehavioral, electrophysiological and histopathological assessments were performed at predefined time points. Results Endoneurial endothelial cell MHC class II expression was observed in normal and inflamed human and mouse peripheral nerves. Adult female Tamoxifen-treated H2-Aa flox/flox ; vWF-iCre/+ did not develop sm-EAN despite extensive MHC class II expression in lymphoid and non-lymphoid tissues. Discussion A conditional MHC class II knockout mouse to study cell- and time-dependent adaptive immune responses in vivo is developed. Initial studies show microvascular endothelial cell MHC class II expression is necessary for peripheral nerve specific autoimmunity, as advocated by human in vitro adaptive immunity and ex vivo transplant rejection studies.
Collapse
|
2
|
Wang X, Starodubtseva MN, Kapron CM, Liu J. Cadmium, von Willebrand factor and vascular aging. NPJ AGING 2023; 9:11. [PMID: 37264012 DOI: 10.1038/s41514-023-00107-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 04/28/2023] [Indexed: 06/03/2023]
Abstract
Vascular aging is a major contributing factor to cardiovascular disease. The aged blood vessels, characterized by vascular wall thickening and stiffening, are instigated by endothelial cell dysfunction induced by oxidative stress and inflammation. von Willebrand Factor (vWF) is a glycoprotein known for its role in coagulation, and plasma levels of vWF are increased with age. Elevated vWF promotes thrombosis, atherosclerotic plaque formation, inflammation and proliferation of vascular smooth muscle cells. Cadmium (Cd) is an environmental pollutant associated with increased morbidity and mortality of cardiovascular disease. At low concentrations, Cd activates pro-survival signaling in endothelial cells, however enhances intima-media thickness and atherogenesis. A non-cytotoxic dose of Cd also increases endothelial vWF expression and secretion in vivo and in vitro. In this review, we summarize the molecular mechanisms underlying vWF-promoted vascular aging-associated pathologies and Cd-induced vWF expression. In addition, we propose that exposure to low-dose Cd is a risk factor for vascular aging, through elevation of plasma vWF.
Collapse
Affiliation(s)
- Xia Wang
- Institute of Microvascular Medicine, The First Affiliated Hospital of Shandong First Medical University& Shandong Provincial Qianfoshan Hospital, Jinan, China
| | - Maria N Starodubtseva
- Gomel State Medical University, Gomel, Belarus
- Institute of Radiobiology of NAS of Belarus, Gomel, Belarus
| | - Carolyn M Kapron
- Department of Biology, Trent University, Peterborough, ON, Canada
| | - Ju Liu
- Institute of Microvascular Medicine, The First Affiliated Hospital of Shandong First Medical University& Shandong Provincial Qianfoshan Hospital, Jinan, China.
| |
Collapse
|
3
|
Mojzisch A, Brehm MA. The Manifold Cellular Functions of von Willebrand Factor. Cells 2021; 10:2351. [PMID: 34572000 PMCID: PMC8466076 DOI: 10.3390/cells10092351] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Revised: 08/26/2021] [Accepted: 09/02/2021] [Indexed: 12/13/2022] Open
Abstract
The plasma glycoprotein von Willebrand factor (VWF) is exclusively synthesized in endothelial cells (ECs) and megakaryocytes, the precursor cells of platelets. Its primary function lies in hemostasis. However, VWF is much more than just a "fishing hook" for platelets and a transporter for coagulation factor VIII. VWF is a true multitasker when it comes to its many roles in cellular processes. In ECs, VWF coordinates the formation of Weibel-Palade bodies and guides several cargo proteins to these storage organelles, which control the release of hemostatic, inflammatory and angiogenic factors. Leukocytes employ VWF to assist their rolling on, adhesion to and passage through the endothelium. Vascular smooth muscle cell proliferation is supported by VWF, and it regulates angiogenesis. The life cycle of platelets is accompanied by VWF from their budding from megakaryocytes to adhesion, activation and aggregation until the end in apoptosis. Some tumor cells acquire the ability to produce VWF to promote metastasis and hide in a shell of VWF and platelets, and even the maturation of osteoclasts is regulated by VWF. This review summarizes the current knowledge on VWF's versatile cellular functions and the resulting pathophysiological consequences of their dysregulation.
Collapse
Affiliation(s)
- Angelika Mojzisch
- Dermatology and Venerology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany;
| | - Maria A. Brehm
- School of Life Sciences, University of Siegen, 57076 Siegen, Germany
| |
Collapse
|
4
|
Dong F, Zhao X, Wang J, Huang X, Li X, Zhang L, Dong H, Liu F, Fan M. Dihydroartemisinin inhibits the expression of von Willebrand factor by downregulation of transcription factor ERG in endothelial cells. Fundam Clin Pharmacol 2020; 35:321-330. [PMID: 33107067 PMCID: PMC7983977 DOI: 10.1111/fcp.12622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 10/21/2020] [Accepted: 10/22/2020] [Indexed: 12/18/2022]
Abstract
Dihydroartemisinin (DHA), a semi‐synthetic derivative of artemisinin, has effective antitumor and anti‐inflammatory actions. von Willebrand factor (vWF), a large multifunctional glycoprotein, has a prominent function in hemostasis and is a key factor in thrombus formation. In addition, vWF has been regarded as a prospective biomarker for the diagnosis of endothelial dysfunction. In our experiment, we observed that 25 μM DHA specifically downregulated the expression of vWF mRNA and protein in human umbilical vein endothelial cells (HUVECs). Further investigations demonstrated that this DHA‐decreased vWF expression was mediated by the transcription factor ERG and not GATA3. Luciferase activity assay confirmed that DHA regulated the ERG binding with the −56 ETS‐binding motif on the human vWF promoter. Thus, the −56 ETS motif on the vWF promoter region regulates the expression of vWF gene which is induced by DHA. Taken together, we proved that DHA decreased the vWF transcription through the downregulation of ERG in HUVECs. As vWF plays a key role in vascular homeostasis, our findings suggest a new role of DHA in vascular diseases.
Collapse
Affiliation(s)
- Fengyun Dong
- Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong, 272029, China
| | - Xinghai Zhao
- Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Jianning Wang
- Department of Urology, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Xin Huang
- Department of Clinical Pharmacy, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Xiao Li
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, Shandong, 250011, China
| | - Liang Zhang
- Shandong Provincial Key Laboratory of Animal Resistance Biology, Institute of Biomedical Sciences, College of Life Sciences, Shandong Normal University, 88 Wenhuadong Street, Jinan, Shandong, 250014, China
| | - Haixin Dong
- Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong, 272029, China
| | - Fuhong Liu
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Mengge Fan
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, 16766 Jingshi Road, Jinan, Shandong, 250014, China.,Graduate School, Shandong First Medical University & Shandong Academy of Medical Sciences, 6699 Qingdao Road, Jinan, 250000, China
| |
Collapse
|
5
|
Haery L, Deverman BE, Matho KS, Cetin A, Woodard K, Cepko C, Guerin KI, Rego MA, Ersing I, Bachle SM, Kamens J, Fan M. Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation. Front Neuroanat 2019; 13:93. [PMID: 31849618 PMCID: PMC6902037 DOI: 10.3389/fnana.2019.00093] [Citation(s) in RCA: 121] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 10/30/2019] [Indexed: 12/14/2022] Open
Abstract
Cell-type-specific expression of molecular tools and sensors is critical to construct circuit diagrams and to investigate the activity and function of neurons within the nervous system. Strategies for targeted manipulation include combinations of classical genetic tools such as Cre/loxP and Flp/FRT, use of cis-regulatory elements, targeted knock-in transgenic mice, and gene delivery by AAV and other viral vectors. The combination of these complex technologies with the goal of precise neuronal targeting is a challenge in the lab. This report will discuss the theoretical and practical aspects of combining current technologies and establish best practices for achieving targeted manipulation of specific cell types. Novel applications and tools, as well as areas for development, will be envisioned and discussed.
Collapse
Affiliation(s)
| | - Benjamin E. Deverman
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, United States
| | | | - Ali Cetin
- Allen Institute for Brain Science, Seattle, WA, United States
| | - Kenton Woodard
- Penn Vector Core, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Connie Cepko
- Department of Genetics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, United States
- Department of Ophthalmology, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, United States
| | | | | | | | | | | | | |
Collapse
|
6
|
Izadpanah P, Khabbzi E, Erfanian S, Jafaripour S, Shojaie M. Case-control study on the association between the GATA2 gene and premature myocardial infarction in the Iranian population. Herz 2019; 46:71-75. [PMID: 31468074 DOI: 10.1007/s00059-019-04841-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 07/05/2019] [Accepted: 07/13/2019] [Indexed: 10/26/2022]
Abstract
In recent decades, due to the high prevalence of coronary artery disease (CAD) and myocardial infarction (MI), numerous studies have attempted to elucidate genetic contributing factors in these complex disorders. A very interesting gene in this regard is GATA-binding protein 2 (GATA2), an important regulator of various gene expressions in vascular endothelial cells. Accordingly, the association of different GATA2 polymorphisms with CAD and MI has already been evaluated. Rs2713604 is a genetic marker whose association with CAD has not been reproduced in previous studies. Considering the importance of replicating the initial association, the present case-control study aimed to examine the association of this intronic variant with premature MI in a sample of the Iranian population. In this study, 193 participants from Jahrom Hospital (Jahrom, Iran) were consecutively recruited during a 1.5-year period, and, following blood sampling, genomic DNA was extracted. We then proceeded to genotype rs2713604 using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method and statistically analyzed the data. After adjustment for hyperlipidemia, hypertension, and type 2 diabetes mellitus, the results of the multivariate regression analysis showed no significant association between rs2713604 and premature MI. Interestingly, the risk allele (A-allele) of rs2713604 displayed a slightly higher frequency among controls compared to cases.
Collapse
Affiliation(s)
- Peyman Izadpanah
- Cardiology Department, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ehsan Khabbzi
- School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
| | - Saiedeh Erfanian
- Research Center for Non-Communicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. .,Department of Advanced Medical Sciences and Technologies, School of Medicine, Jahrom University of Medical Sciences, Motahhari Street, 74148-46199, Jahrom, Iran.
| | - Simin Jafaripour
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Vakil abad Blv., 99191-91778, Mashhad, Iran.
| | - Mohammad Shojaie
- Research Center for Non-Communicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
| |
Collapse
|
7
|
Mojiri A, Alavi P, Lorenzana Carrillo MA, Nakhaei-Nejad M, Sergi CM, Thebaud B, Aird WC, Jahroudi N. Endothelial cells of different organs exhibit heterogeneity in von Willebrand factor expression in response to hypoxia. Atherosclerosis 2019; 282:1-10. [PMID: 30665023 DOI: 10.1016/j.atherosclerosis.2019.01.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 12/17/2018] [Accepted: 01/09/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND AIMS We have previously demonstrated that in response to hypoxia, von Willebrand factor (VWF) expression is upregulated in lung and heart endothelial cells both in vitro and in vivo, but not in kidney endothelial cells. The aim of our current study was to determine whether endothelial cells of different organs employ distinct molecular mechanisms to mediate VWF response to hypoxia. METHODS We used cultured human primary lung, heart and kidney endothelial cells to determine the activation of endogenous VWF as well as exogenously expressed VWF promoter in response to hypoxia. Chromatin immunoprecipitation and siRNA knockdown analyses were used to determine the roles of VWF promoter associated transacting factors in mediating its hypoxia response. Platelet aggregates formations in vascular beds of mice were used as a marker for potential functional consequences of hypoxia-induced VWF upregulation in vivo. RESULTS Our analyses demonstrated that while Yin Yang 1 (YY1) and specificity protein 1 (Sp1) participate in the hypoxia-induced upregulation of VWF specifically in lung endothelial cells, GATA6 mediates this process specifically in heart endothelial cells. In both cell types, the response to hypoxia involves the decreased association of the NFIB repressor with the VWF promoter, and the increased acetylation of the promoter-associated histone H4. In mice exposed to hypoxia, the upregulation of VWF expression was concomitant with the presence of thrombi in heart and lung, but not kidney vascular beds. CONCLUSIONS Heart and lung endothelial cells demonstrated VWF upregulation in response to hypoxia, using distinct mechanisms, while this response was lacking in kidney endothelial cells.
Collapse
Affiliation(s)
- Anahita Mojiri
- Department of Medicine, University of Alberta, Edmonton, Canada
| | - Parnian Alavi
- Department of Medicine, University of Alberta, Edmonton, Canada
| | | | | | - Consolato M Sergi
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Bernard Thebaud
- Ottawa Hospital Research Institute & CHEO Research Institute, Pediatrics, Ottawa, Ontario, Canada
| | - William C Aird
- Center for Vascular Biology Research and Division of Molecular and Vascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Nadia Jahroudi
- Department of Medicine, University of Alberta, Edmonton, Canada.
| |
Collapse
|
8
|
Nakhaei-Nejad M, Farhan M, Mojiri A, Jabbari H, Murray AG, Jahroudi N. Regulation of von Willebrand Factor Gene in Endothelial Cells That Are Programmed to Pluripotency and Differentiated Back to Endothelial Cells. Stem Cells 2019; 37:542-554. [PMID: 30682218 DOI: 10.1002/stem.2978] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 11/13/2018] [Accepted: 12/19/2018] [Indexed: 12/13/2022]
Abstract
Endothelial cells play a central role in physiological function and pathophysiology of blood vessels in health and disease. However, the molecular mechanism that establishes the endothelial phenotype, and contributes to its signature cell type-specific gene expression, is not yet understood. We studied the regulation of a highly endothelial-specific gene, von Willebrand factor (VWF), in induced pluripotent stem cells generated from primary endothelial cells (human umbilical vein endothelial cells [HUVEC] into a pluripotent state [HiPS]) and subsequently differentiated back into endothelial cells. This allowed us to explore how VWF expression is regulated when the endothelial phenotype is revoked (endothelial cells to HiPS), and re-established (HiPS back to endothelial cells [EC-Diff]). HiPS were generated from HUVECs, their pluripotency established, and then differentiated back to endothelial cells. We established phenotypic characteristics and robust angiogenic function of EC-Diff. Gene array analyses, VWF chromatin modifications, and transacting factors binding assays were performed on the three cell types (HUVEC, HiPS, and EC-Diff). The results demonstrated that generally cohorts of transacting factors that function as transcriptional activators, and those that contribute to histone acetylation and DNA demethylation, were significantly decreased in HiPS compared with HUVECs and EC-Diff. In contrast, there were significant increases in the gene expression levels of epigenetic modifiers that function as methyl transferases in HiPS compared with endothelial cells. The results demonstrated that alterations in chromatin modifications of the VWF gene, in addition to expression and binding of transacting factors that specifically function as activators, are responsible for establishing endothelial specific regulation of the VWF gene. Stem Cells 2019;37:542-554.
Collapse
Affiliation(s)
| | - Maikel Farhan
- Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Anahita Mojiri
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Hosna Jabbari
- Department of Computer Science, University of Vermont, Burlington, Vermont, USA
| | - Allan G Murray
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Nadia Jahroudi
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
9
|
Wang X, Dong F, Wang F, Yan S, Chen X, Tozawa H, Ushijima T, Kapron CM, Wada Y, Liu J. Low dose cadmium upregulates the expression of von Willebrand factor in endothelial cells. Toxicol Lett 2018; 290:46-54. [PMID: 29571895 DOI: 10.1016/j.toxlet.2018.03.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 03/01/2018] [Accepted: 03/18/2018] [Indexed: 11/17/2022]
Abstract
Cadmium (Cd) is a persistent and widespread environmental pollutant of continuing worldwide concern. Previous studies have suggested that Cd exposure increases the risk of cardiovascular diseases, such as atherosclerosis and hypertension. However, the underlying mechanisms are poorly understood. In this study, we observed that low dose Cd treatment induced von Willebrand factor (vWF) expression in vascular endothelial cells in mouse lung and kidney tissues. In vitro analysis showed that 1 μM Cd specifically upregulated vWF mRNA and protein expression in human umbilical vein endothelial cells (HUVECs), indicating that Cd targets vascular endothelial cells even at relatively low concentrations. Further study demonstrated that nuclear factor kappa B (NF-κB) and GATA3, two established transcription regulators of the vWF gene, were not altered in the presence of Cd. However, ETS-related gene (ERG) was significantly induced by 1 μM Cd. When ERG was knocked down by siRNA, Cd induced upregulation of vWF was totally blocked. Chromatin immunoprecipitation (ChIP) assay showed that Cd increases the binding of ERG on the -56 ETS motif on the human vWF promoter. These results indicated that ERG mediated the increased expression of vWF by Cd. Since vWF is a key regulator for vascular homeostasis, our findings may provide a novel mechanism for understanding low dose Cd induced development of vascular diseases.
Collapse
Affiliation(s)
- Xia Wang
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Fengyun Dong
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Fufang Wang
- Department of Geriatrics, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, Shandong, China; Key laboratory of Cardiovascular Proteomics of Shandong Province, 107 Wenhua Xi Road, Jinan, Shandong, China
| | - Suhua Yan
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong, 250014 China
| | - Xiaocui Chen
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong, 250014, China
| | - Hideto Tozawa
- The Research Center for Advanced Science and Technology, and Isotope Science Center, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Toshiyuki Ushijima
- The Research Center for Advanced Science and Technology, and Isotope Science Center, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Carolyn M Kapron
- Department of Biology, Trent University, Peterborough, Ontario, K9L 0G2, Canada
| | - Youichiro Wada
- The Research Center for Advanced Science and Technology, and Isotope Science Center, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Ju Liu
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong, 250014, China.
| |
Collapse
|
10
|
GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature. Oncotarget 2017; 8:110517-110529. [PMID: 29299165 PMCID: PMC5746400 DOI: 10.18632/oncotarget.22806] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 11/13/2017] [Indexed: 12/29/2022] Open
Abstract
Lung adenocarcinoma (LAC) is the leading cause of cancer-related death worldwide. Aberrant expression of genes expressed preferentially in the lung tumor vasculature may yield clues for prognosis and treatment. Von Willebrand factor (vWF) is a large multifunctional glycoprotein with a well-known function in hemostasis. However, vWF has been reported to exert an anti-tumor effect, independent of its role in hemostasis. We investigated the expression of vWF in LAC through immunohistochemical staining of tumor tissue microarrays (TMAs). We found that vWF was overexpressed preferentially in the tumor vasculature of LAC compared with the adjacent tissue vasculature. Consistently, elevated vWF expression was found in endothelial cells (ECs) of fresh human LAC tissues and transplanted mouse LAC tissues. To understand the mechanism underlying vWF up-regulation in LAC vessels, we established a co-culture system. In this system, conditioned media (CM) collected from A549 cells increased vWF expression in human umbilical vein endothelial cells (HUVECs), suggesting enhanced expression is regulated by the LAC secretome. Subsequent studies revealed that the transcription factor GATA3, but not ERG, a known regulator of vWF transcription in vascular cells, mediated the vWF elevation. Chromatin immunoprecipitation (ChIP) assays validated that GATA3 binds directly to the +220 GATA binding motif on the human vWF promoter and A549 conditioned media significantly increases the binding of GATA3. Taken together, we demonstrate that vWF expression in ECs of LAC is elevated by the cancer cell-derived secretome through enhanced GATA3-mediated transcription.
Collapse
|
11
|
Mashreghi M, Azarpara H, Bazaz MR, Jafari A, Masoudifar A, Mirzaei H, Jaafari MR. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J Cell Physiol 2017; 233:2949-2965. [DOI: 10.1002/jcp.26049] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 06/12/2017] [Indexed: 12/20/2022]
Affiliation(s)
- Mohammad Mashreghi
- NanotechnologyResearch Center; Mashhad University of Medical Sciences; Mashhad Iran
- School of Pharmacy; Mashhad University of Medical Sciences; Mashhad Iran
| | - Hassan Azarpara
- School of Medicine; Iran University of Medical Sciences; Tehran Iran
| | - Mahere R. Bazaz
- Division of Biotechnology, Faculty of Veterinary Medicine; Ferdowsi University of Mashhad; Mashhad Iran
| | - Arash Jafari
- School of Medicine; Birjand University of Medical Sciences; Birjand Iran
| | - Aria Masoudifar
- Department of Molecular Biotechnology, Cell Science Research Center; Royan Institute for Biotechnology; ACECR Isfahan Iran
| | - Hamed Mirzaei
- Department of Medical Biotechnology, School of Medicine; Mashhad University of Medical Sciences; Mashhad Iran
| | - Mahmoud R. Jaafari
- NanotechnologyResearch Center; Mashhad University of Medical Sciences; Mashhad Iran
- School of Pharmacy; Mashhad University of Medical Sciences; Mashhad Iran
| |
Collapse
|
12
|
Mojiri A, Stoletov K, Lorenzana Carrillo MA, Willetts L, Jain S, Godbout R, Jurasz P, Sergi CM, Eisenstat DD, Lewis JD, Jahroudi N. Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin. Oncotarget 2017; 8:13015-13029. [PMID: 28035064 PMCID: PMC5355073 DOI: 10.18632/oncotarget.14273] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 11/30/2016] [Indexed: 02/04/2023] Open
Abstract
Von Willebrand factor (VWF) is a highly adhesive procoagulant molecule that mediates platelet adhesion to endothelial and subendothelial surfaces. Normally it is expressed exclusively in endothelial cells (ECs) and megakaryocytes. However, a few studies have reported VWF detection in cancer cells of non-endothelial origin, including osteosarcoma. A role for VWF in cancer metastasis has long been postulated but evidence supporting both pro- and anti-metastatic roles for VWF has been presented. We hypothesized that the role of VWF in cancer metastasis is influenced by its cellular origin and that cancer cell acquisition of VWF expression may contribute to enhanced metastatic potential. We demonstrated de novo expression of VWF in glioma as well as osteosarcoma cells. Endothelial monolayer adhesion, transmigration and extravasation capacities of VWF expressing cancer cells were shown to be enhanced compared to non-VWF expressing cells, and were significantly reduced as a result of VWF knock down. VWF expressing cancer cells were also detected in patient tumor samples of varying histologies. Analyses of the mechanism of transcriptional activation of the VWF in cancer cells demonstrated a pattern of trans-activating factor binding and epigenetic modifications consistent overall with that observed in ECs. These results demonstrate that cancer cells of non-endothelial origin can acquire de novo expression of VWF, which can enhance processes, including endothelial and platelet adhesion and extravasation, that contribute to cancer metastasis.
Collapse
Affiliation(s)
- Anahita Mojiri
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | | | | | - Lian Willetts
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Saket Jain
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Roseline Godbout
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Paul Jurasz
- Department of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Consolato M. Sergi
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - David D. Eisenstat
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
- Departments of Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - John D. Lewis
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Nadia Jahroudi
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
13
|
Hartmann D, Fiedler J, Sonnenschein K, Just A, Pfanne A, Zimmer K, Remke J, Foinquinos A, Butzlaff M, Schimmel K, Maegdefessel L, Hilfiker-Kleiner D, Lachmann N, Schober A, Froese N, Heineke J, Bauersachs J, Batkai S, Thum T. MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation 2016; 134:1973-1990. [PMID: 27780851 DOI: 10.1161/circulationaha.116.022478] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 10/03/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND The transcription factor GATA2 orchestrates the expression of many endothelial-specific genes, illustrating its crucial importance for endothelial cell function. The capacity of this transcription factor in orchestrating endothelial-important microRNAs (miRNAs/miR) is unknown. METHODS Endothelial GATA2 was functionally analyzed in human endothelial cells in vitro. Endogenous short interfering RNA-mediated knockdown and lentiviral-based overexpression were applied to decipher the capacity of GATA2 in regulating cell viability and capillary formation. Next, the GATA2-dependent miR transcriptome was identified by using a profiling approach on the basis of quantitative real-time polymerase chain reaction. Transcriptional control of miR promoters was assessed via chromatin immunoprecipitation, luciferase promoter assays, and bisulfite sequencing analysis of sites in proximity. Selected miRs were modulated in combination with GATA2 to identify signaling pathways at the angiogenic cytokine level via proteome profiler and enzyme-linked immunosorbent assays. Downstream miR targets were identified via bioinformatic target prediction and luciferase reporter gene assays. In vitro findings were translated to a mouse model of carotid injury in an endothelial GATA2 knockout background. Nanoparticle-mediated delivery of proangiogenic miR-126 was tested in the reendothelialization model. RESULTS GATA2 gain- and loss-of-function experiments in human umbilical vein endothelial cells identified a key role of GATA2 as master regulator of multiple endothelial functions via miRNA-dependent mechanisms. Global miRNAnome-screening identified several GATA2-regulated miRNAs including miR-126 and miR-221. Specifically, proangiogenic miR-126 was regulated by GATA2 transcriptionally and targeted antiangiogenic SPRED1 and FOXO3a contributing to GATA2-mediated formation of normal vascular structures, whereas GATA2 deficiency led to vascular abnormalities. In contrast to GATA2 deficiency, supplementation with miR-126 normalized vascular function and expression profiles of cytokines contributing to proangiogenic paracrine effects. GATA2 silencing resulted in endothelial DNA hypomethylation leading to induced expression of antiangiogenic miR-221 by GATA2-dependent demethylation of a putative CpG island in the miR-221 promoter. Mechanistically, a reverted GATA2 phenotype by endogenous suppression of miR-221 was mediated through direct proangiogenic miR-221 target genes ICAM1 and ETS1. In a mouse model of carotid injury, GATA2 was reduced, and systemic supplementation of miR-126-coupled nanoparticles enhanced miR-126 availability in the carotid artery and improved reendothelialization of injured carotid arteries in vivo. CONCLUSIONS GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases.
Collapse
Affiliation(s)
- Dorothee Hartmann
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Jan Fiedler
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Kristina Sonnenschein
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Annette Just
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Angelika Pfanne
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Karina Zimmer
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Janet Remke
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Ariana Foinquinos
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Malte Butzlaff
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Katharina Schimmel
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Lars Maegdefessel
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Denise Hilfiker-Kleiner
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Nico Lachmann
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Andreas Schober
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Natali Froese
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Jörg Heineke
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Johann Bauersachs
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Sandor Batkai
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.)
| | - Thomas Thum
- From Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Germany (D.H., J.F., K.S., A.J., A.P., K.Z., J.R., A.F., K.S., S.B., T.T.); Department of Cardiology and Angiology, Hannover Medical School, Germany (K.S., D.H.-K., N.F., J.H., J.B.); Cellular Neurophysiology, Center of Physiology, Hannover Medical School, Germany (M.B.); Department of Vascular and Endovascular Surgery, Technical University Munich, Germany (L.M.); Cluster of Excellence REBIRTH, Hannover Medical School, Germany (D.H.-K., N.F., J.H., J.B., T.T.); JRG Translational Hematology of Congenital Disease, Cluster of Excellence REBIRTH, Institute of Experimental Hematology, Hannover Medical School, Germany (N.L.); Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (A.S.); DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany (A.S.); and National Heart and Lung Institute, Imperial College London, UK (T.T.).
| |
Collapse
|
14
|
Singh B, Biswas I, Bhagat S, Surya Kumari S, Khan GA. HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway. Eur J Immunol 2016; 46:2388-2400. [PMID: 27480067 DOI: 10.1002/eji.201646386] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 06/27/2016] [Accepted: 07/29/2016] [Indexed: 12/14/2022]
Abstract
Increased plasma level of von Willebrand Factor (vWF) is associated with major cardiovascular diseases. We previously reported that multimeric vWF binds to NO synthase and inhibits insulin-induced production of NO, thus promoting insulin resistance during acute hypoxia (AH). However, the transcriptional regulation of vWF during AH is not clearly understood. Here, we investigated the mechanisms underlying the upregulation of vwf in mice. AH significantly upregulates the tlr2, tlr3, myd88, and vwf expression and phosphorylation of specificity protein 1 (SP1). Furthermore, AH significantly upregulates high mobility group box-1 (HMGB1) in a time-dependent manner. Moreover, a TLR2 agonist upregulates vWF but a TLR3 agonist does not. Pretreatment with an HMGB1 inhibitor, TLR2-immunoneutralizing antibody, or SP1 inhibitor significantly inhibits vWF expression. Furthermore, Tlr2 silencing completely inhibited MYD88, vWF expression, and SP1 phosphorylation. However, pretreatment with glycyrrhizic acid or silencing of Tlr2 completely blocks binding of Sp1 to the Vwf promoter, thus inhibiting its expression, and enhances insulin resistance during AH. Patients with type 2 diabetes mellitus also showed significantly elevated levels of HMGB1, TLR2, SP1, and vWF, thereby supporting the results of the murine model of AH. Taken together, HMGB1 upregulates vWF in vivo through the TLR2-MYD88-SP1 pathway in mice.
Collapse
Affiliation(s)
- Bandana Singh
- Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India
| | - Indranil Biswas
- Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India
| | - Saumya Bhagat
- Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India
| | - Sarada Surya Kumari
- Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India
| | - Gausal A Khan
- Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.
| |
Collapse
|
15
|
Li Y, Li L, Dong F, Guo L, Hou Y, Hu H, Yan S, Zhou X, Liao L, Allen TD, Liu JU. Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Exp Ther Med 2015; 10:1743-1749. [PMID: 26640545 PMCID: PMC4665708 DOI: 10.3892/etm.2015.2721] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Accepted: 08/07/2015] [Indexed: 01/17/2023] Open
Abstract
The von Willebrand factor (vWF) is a plasma glycoprotein that plays an essential role in hemostasis by supporting platelet adhesion and thrombus formation in response to vascular injury. Plasma levels of vWF are an independent risk factor for patients with acute myocardial infarction (AMI); however, clinical data have demonstrated a marked variation of vWF levels in patients with AMI, the reason for which has not yet been identified. In the present study, a rat model of ST-segment elevation AMI was established, and cardiac and peripheral blood was collected for a time-course examination of the plasma levels of vWF and tumor necrosis factor-α (TNF-α). The level of vWF in the blood plasma increased, peaked at 1 h and decreased to normal levels by day 7 following AMI, while the level of TNF-α peaked at 24 h and remained elevated until day 7. The effects of TNF-α on vWF secretion and expression were examined in cultured human umbilical vascular endothelial cells (HUVECs). TNF-α treatment increased vWF secretion from the HUVECs but inhibited the mRNA and protein expression of vWF in the HUVECs. These results indicate that vWF secretion from endothelial cells is transiently elevated following AMI, and then decreases as the expression of vWF is inhibited by TNF-α. The present study increases the understanding of the pathophysiology of vWF and indicates that the determination of vWF levels may be useful in the clinical evaluation of AMI.
Collapse
Affiliation(s)
- Yan Li
- Children's Health Care Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Liqun Li
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Fengyun Dong
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Ling Guo
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Yinglong Hou
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Hesheng Hu
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Suhua Yan
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Xiaojun Zhou
- Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Lin Liao
- Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| | - Thaddeus D Allen
- G.W. Hooper Research Foundation, University of California at San Francisco, San Francisco, CA 94143-0552, USA
| | - J U Liu
- Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
| |
Collapse
|
16
|
Brott DA, Katein A, Thomas H, Lawton M, Montgomery RR, Richardson RJ, Louden CS. Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 2014; 42:672-83. [PMID: 24499802 DOI: 10.1177/0192623313518664] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Pharmacologically, vasoactive agents targeting endothelial and/or smooth muscle cells (SMC) are known to cause acute drug-induced vascular injury (DIVI) and the resulting pathology is due to endothelial cell (EC) perturbation, activation, and/or injury. Alteration in EC structure and/or function may be a critical event in vascular injury and, therefore, evaluation of the circulatory kinetic profile and secretory pattern of EC-specific proteins such as VWF and VWFpp could serve as acute vascular injury biomarkers. In rat and dog models of DIVI, this profile was determined using pharmacologically diverse agents associated with functional stimulation/perturbation (DDAVP), pathological activation (lipopolysaccharide [LPS]/endotoxin), and structural damage (fenoldopam [FD], dopamine [DA], and potassium channel opener (PCO) ZD6169). In rats, FD caused moderate DIVI and time-related increase in plasma VWF levels ∼33% while in control rats VWF increased ∼5%. In dogs, VWF levels transiently increased ∼30% when there was morphologic evidence of DIVI by DA or ZD6169. However, in dogs, VWFpp increased >60-fold (LPS) and >6-fold (DDAVP), respectively. This was in comparison to smaller dynamic 1.38-fold (LPS) and 0.54-fold (DDAVP) increases seen in plasma VWF. Furthermore, DA was associated with a dose-dependent increase in plasma VWFpp. In summary, VWF and VWFpp can discriminate between physiological and pathological perturbation, activation, and injury to ECs.
Collapse
Affiliation(s)
- David A Brott
- Global Safety Assessment, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
| | - Anne Katein
- Global Safety Assessment, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
| | - Heath Thomas
- Safety Assessment, Pathology, GlaxoSmithKline, King of Prussia, Pennsylvania, USA
| | - Michael Lawton
- Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut, USA
| | | | - Rudy J Richardson
- Department of Environmental Health Sciences, The University of Michigan, Ann Arbor, Michigan, USA
| | - Calvert S Louden
- Drug Safety Sciences, Janssen Pharmaceuticals, Spring House, Pennsylvania, USA
| |
Collapse
|
17
|
Minami T. Genome- and epigenome-wide analysis of endothelial cell activation and inflammation. Inflamm Regen 2014. [DOI: 10.2492/inflammregen.34.094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
18
|
Chen T, Wang J, Xue B, Kong Q, Liu Z, Yu B. Identification and characterization of a novel porcine endothelial cell-specific Tie1 promoter. Xenotransplantation 2013; 20:438-48. [PMID: 24112087 DOI: 10.1111/xen.12059] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Accepted: 08/14/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND The use of a transgenic pig for xenotransplantation and as a cardiovascular disease model has caught much attention in the past decades. The vascular endothelial cell is the primary modification target for the application of genetically modified pigs in this field. However, the powerful porcine endothelial cell-specific promoter is still so rare that the mouse and human promoters are commonly used. In the study, the porcine Tie1 (sTie1) promoter was identified and characterized as a potential endothelial cell-specific promoter to generate a cardiovascular disease model. METHODS Tie1 promoters with different lengths of 5'-regulatory regions were cloned, and major putative DNA-binding motifs were mutated by site-directed mutagenesis. All fragments were ligated into the luciferase reporter system and were transiently transfected into endothelial cells to identify luciferase activity using a dual luciferase reporter assay. RESULTS The luciferase activities of sTie1 promoters with different lengths of the 5'-regulatory region were tested. Results showed that the luciferase activity of the 1234-bp sTie1 fragment was the strongest compared with that of others (P < 0.001). Site-directed mutagenesis in transcription-factor-binding sites, including Ets, GATA, and AP2, verified their key roles in regulating transcription, especially sites Ets (-103), GATA (-211), and AP2 (-3). The activities of Tie1 promoters from pig, human, and mouse were significantly different in pig iliac endothelial cells (PIECs) (P < 0.001), and the sTie1 promoter showed the highest activity. Moreover, sTie1 promoter activity could be detected in porcine embryo fibroblasts and skeletal muscle cells. CONCLUSIONS The sTie1 promoter shows a highly conserved sequence compared with the Tie1 promoters in human and mouse, but it has a greater activity in the porcine endothelial cell line than that of human and mouse promoters. Thus, sTie1 will be a valuable tool for generating a pig cardiovascular disease model.
Collapse
Affiliation(s)
- Tao Chen
- The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, Heilongjiang, China; Cardiology Division, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | | | | | | | | | | |
Collapse
|
19
|
Mojiri A, Nakhaii-Nejad M, Phan WL, Kulak S, Radziwon-Balicka A, Jurasz P, Michelakis E, Jahroudi N. Hypoxia results in upregulation and de novo activation of von Willebrand factor expression in lung endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33:1329-38. [PMID: 23580145 DOI: 10.1161/atvbaha.113.301359] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Increased von Willebrand factor (VWF) levels in lungs are associated with diseases such as pulmonary hypertension. The objective of our study was to determine the mechanism of increased VWF levels in conditions, such as hypoxia, which contribute to pulmonary hypertension. APPROACH AND RESULTS We have previously reported generation of transgenic mice that express LacZ transgene under the regulation of lung- and brain-specific transcriptional regulatory elements of the VWF gene. Hypoxia exposure of these transgenic mice resulted in increased VWF and LacZ mRNA levels as well as redistribution of their expression from primarily larger vessels in the lungs to microvessels. Exposure of cultured lung microvascular endothelial cells to hypoxia demonstrated that VWF upregulation was accompanied by increased platelet binding. Transcription upregulation was mediated through inhibition of the repressor nuclear factor-IB association with the VWF promoter, and increased nuclear translocation of the transcription factor YY1 and association with its cognate binding site on the VWF gene. Knockdown of YY1 expression abolished the hypoxia-induced upregulation and reduced basal level of VWF. CONCLUSIONS These analyses demonstrate that hypoxia induces a phenotypic shift, accompanied by modulation of nuclear factor-IB and YY1 activities, in microvascular endothelial cells of the lungs to support VWF promoter activation.
Collapse
Affiliation(s)
- Anahita Mojiri
- Departments of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | | | | | | | | | | | | | | |
Collapse
|
20
|
A mechanistic role for DNA methylation in endothelial cell (EC)-enriched gene expression: relationship with DNA replication timing. Blood 2013; 121:3531-40. [PMID: 23449636 DOI: 10.1182/blood-2013-01-479170] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Proximal promoter DNA methylation has been shown to be important for regulating gene expression. However, its relative contribution to the cell-specific expression of endothelial cell (EC)-enriched genes has not been defined. We used methyl-DNA immunoprecipitation and bisulfite conversion to analyze the DNA methylation profile of EC-enriched genes in ECs vs nonexpressing cell types, both in vitro and in vivo. We show that prototypic EC-enriched genes exhibit functional differential patterns of DNA methylation in proximal promoter regions of most (eg, CD31, von Willebrand factor [vWF], VE-cadherin, and intercellular adhesion molecule-2), but not all (eg, VEGFR-1 and VEGFR-2), EC-enriched genes. Comparable findings were evident in cultured ECs, human blood origin ECs, and murine aortic ECs. Promoter-reporter episomal transfection assays for endothelial nitric oxide synthase, VE-cadherin, and vWF indicated functional promoter activity in cell types where the native gene was not active. Inhibition of DNA methyltransferase activity indicated important functional relevance. Importantly, profiling DNA replication timing patterns indicated that EC-enriched gene promoters with differentially methylated regions replicate early in S-phase in both expressing and nonexpressing cell types. Collectively, these studies highlight the functional importance of promoter DNA methylation in controlling vascular EC gene expression.
Collapse
|
21
|
Epigenetically coordinated GATA2 binding is necessary for endothelium-specific endomucin expression. EMBO J 2011; 30:2582-95. [PMID: 21666600 DOI: 10.1038/emboj.2011.173] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2010] [Accepted: 05/01/2011] [Indexed: 11/08/2022] Open
Abstract
GATA2 is well recognized as a key transcription factor and regulator of cell-type specificity and differentiation. Here, we carried out comparative chromatin immunoprecipitation with comprehensive sequencing (ChIP-seq) to determine genome-wide occupancy of GATA2 in endothelial cells and erythroids, and compared the occupancy to the respective gene expression profile in each cell type. Although GATA2 was commonly expressed in both cell types, different GATA2 bindings and distinct cell-specific gene expressions were observed. By using the ChIP-seq with epigenetic histone modifications and chromatin conformation capture assays; we elucidated the mechanistic regulation of endothelial-specific GATA2-mediated endomucin gene expression, that was regulated by the endothelial-specific chromatin loop with a GATA2-associated distal enhancer and core promoter. Knockdown of endomucin markedly attenuated endothelial cell growth, migration and tube formation. Moreover, abrogation of GATA2 in endothelium demonstrated not only a reduction of endothelial-specific markers, but also induction of mesenchymal transition promoting gene expression. Our findings provide new insights into the correlation of endothelial-expressed GATA2 binding, epigenetic modification, and the determination of endothelial cell specificity.
Collapse
|
22
|
The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 2011; 82:1-17. [PMID: 21605981 DOI: 10.1016/j.critrevonc.2011.04.007] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 03/18/2011] [Accepted: 04/21/2011] [Indexed: 11/23/2022] Open
Abstract
Hematopoiesis involves an elaborate regulatory network of transcription factors that coordinates the expression of multiple downstream genes, and maintains homeostasis within the hematopoietic system through the accurate orchestration of cellular proliferation, differentiation and survival. As a result, defects in the expression levels or the activity of these transcription factors are intimately linked to hematopoietic disorders, including leukemia. The GATA family of nuclear regulatory proteins serves as a prototype for the action of lineage-restricted transcription factors. GATA1 and GATA2 are expressed principally in hematopoietic lineages, and have essential roles in the development of multiple hematopoietic cells, including erythrocytes and megakaryocytes. Moreover, GATA2 is crucial for the proliferation and maintenance of hematopoietic stem cells and multipotential progenitors. In this review, we summarize the current knowledge regarding the biological properties and functions of the GATA2 transcription factor in normal and malignant hematopoiesis.
Collapse
|
23
|
Crouthamel MH, Kelly EJ, Ho RJY. Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers. Transgenic Res 2011; 21:113-30. [PMID: 21538071 DOI: 10.1007/s11248-011-9512-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Accepted: 04/13/2011] [Indexed: 12/11/2022]
Abstract
For many CNS acting drugs, penetration into the central nervous system (CNS) is limited by the blood-CNS-barriers. In an effort to quantitate the role of the protein components that make up the blood-CNS-barriers, we created transgenic mice that allow conditional gene knockout using Cre/loxP technology. We targeted the expression of Cre-recombinase to the choroid plexus (the blood-cerebral spinal fluid barrier) using the lymphotropic papovavirus control region (LPVcr) and to brain endothelium (the blood-brain-barrier) using the proximal promoter region of the human von Willebrand Factor gene (hVWF-f). We verified that LPVcr restricts expression to the choroid plexus in adult mice by using the LPVcr to drive n-LacZ expression in transgenic mice. The LPV-Cre and hVWF-Cre plasmids were then constructed and tested for Cre-recombinase function in vitro, and subsequently used to create transgenic mice. The resulting transgenic mice were characterized for cell-type specific Cre-mediated endonuclease activity by crossing them with transgenic mice containing a loxP-flanked-LacZ/EGFP dual reporter gene Z/EG. The dual Cre-Z/EG transgenic offspring were evaluated for the location of EGFP mRNA expression by reverse transcriptase PCR and for protein expression by immunohistochemistry. Immunohistochemistry for EGFP verified expression in the target cells, and no ectopic expression outside of the expected cell types. The LPV-Cre.0607 transgenic line expressed functional Cre only in the choroid plexus and hVWF-Cre.1304 line in brain endothelium.
Collapse
Affiliation(s)
- Matthew H Crouthamel
- Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195-7610, USA
| | | | | |
Collapse
|
24
|
Vascular bed-specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle. Blood 2010; 117:342-51. [PMID: 20980682 DOI: 10.1182/blood-2010-06-287987] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
A region of the human von Willebrand factor (VWF) gene between -2812 and the end of the first intron (termed vWF2) was previously shown to direct expression in the endothelium of capillaries and a subset of larger blood vessels in the heart and skeletal muscle. Here, our goal was to delineate the DNA sequences responsible for this effect. A series of constructs containing deletions or mutations of vWF2 coupled to LacZ were targeted to the Hprt locus of mice, and the resulting animals were analyzed for reporter gene expression. The findings demonstrate that DNA sequences between -843 and -620 are necessary for expression in capillary but not large vessel endothelium in heart and skeletal muscle. Further, expression of VWF in capillaries and larger vessels of both tissues required the presence of a native or heterologous intron. In vitro assays implicated a role for ERG-binding ETS motif at -56 in mediating basal expression of VWF. In Hprt-targeted mice, mutation of the ETS consensus motif resulted in loss of LacZ expression in the endothelium of the heart and skeletal muscle. Together, these data indicate that distinct DNA modules regulate vascular bed-specific expression of VWF.
Collapse
|
25
|
Andrade FK, Costa R, Domingues L, Soares R, Gama M. Improving bacterial cellulose for blood vessel replacement: Functionalization with a chimeric protein containing a cellulose-binding module and an adhesion peptide. Acta Biomater 2010; 6:4034-41. [PMID: 20438872 DOI: 10.1016/j.actbio.2010.04.023] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2009] [Revised: 04/24/2010] [Accepted: 04/27/2010] [Indexed: 02/02/2023]
Abstract
Chimeric proteins containing a cellulose-binding module (CBM) and an adhesion peptide (RGD or GRGDY) were produced and used to improve the adhesion of human microvascular endothelial cells (HMEC) to bacterial cellulose (BC). The effect of these proteins on the HMEC-BC interaction was studied. The results obtained demonstrated that recombinant proteins containing adhesion sequences were able to significantly increase the attachment of HMEC to BC surfaces, especially the RGD sequence. The images obtained by scanning electron microscopy showed that the cells on the RGD-treated BC present a more elongated morphology 48h after cell seeding. The results also showed that RGD decreased the in-growth of HMEC cells through the BC and stimulated the early formation of cord-like structures by these endothelial cells. Thus, the use of recombinant proteins containing a CBM domain, with high affinity and specificity for cellulose surfaces allows control of the interaction of this material with cells. CBM may be combined with virtually any biologically active protein for the modification of cellulose-based materials, for in vitro or in vivo applications.
Collapse
|
26
|
Le Bras A, Samson C, Trentini M, Caetano B, Lelievre E, Mattot V, Beermann F, Soncin F. VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One 2010; 5:e12156. [PMID: 20808444 PMCID: PMC2922337 DOI: 10.1371/journal.pone.0012156] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2010] [Accepted: 07/20/2010] [Indexed: 11/24/2022] Open
Abstract
Angiogenesis is the process by which new blood vessels arise from existing ones by the budding out of endothelial cell capillaries from the luminal side of blood vessels. Blood vessel formation is essential for organ development during embryogenesis and is associated with several physiological and pathological processes, such as wound healing and tumor development. The VE-statin/egfl7 gene is specifically expressed in endothelial cells during embryonic development and in the adult. We studied here the regulatory mechanisms that control this tissue-specific expression. RT-qPCR analyses showed that the specificity of expression of VE-statin/egfl7 in endothelial cells is not shared with its closest neighbor genes notch1 and agpat2 on the mouse chromosome 2. Chromatin-immunoprecipitation analysis of histone modifications at the VE-statin/egfl7 locus showed that the chromatin is specifically opened in endothelial cells, but not in fibroblasts at the transcription start sites. A 13 kb genomic fragment of promoter was cloned and analyzed by gene reporter assays which showed that two conserved regions are important for the specific expression of VE-statin/egfl7 in endothelial cells; a −8409/−7563 enhancer and the −252/+38 region encompassing the exon-1b transcription start site. The latter contains essential GATA and ETS-binding sites, as assessed by linker-scanning analysis and site-directed mutagenesis. An analysis of expression of the ETS and GATA transcription factors showed that Erg, Fli-1 and GATA-2 are the most highly expressed factors in endothelial cells. Erg and GATA-2 directly control the expression of the endogenous VE-statin/egfl7 while Fli-1 probably exerts an indirect control, as assessed by RNA interference and chromatin immunoprecipitation. This first detailed analysis of the mechanisms that govern the expression of the VE-statin/egfl7 gene in endothelial cells pinpoints the specific importance of ETS and GATA factors in the specific regulation of genes in this cell lineage.
Collapse
Affiliation(s)
- Alexandra Le Bras
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Chantal Samson
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Matteo Trentini
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Bertrand Caetano
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Etienne Lelievre
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Virginie Mattot
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
| | - Friedrich Beermann
- Swiss Institute for Experimental Cancer Research (ISREC), Centre de Phénotypage Génomique (CPG), School of Life Sciences, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland
| | - Fabrice Soncin
- CNRS, Institut de Biologie de Lille, UMR 8161, Equipe labellisée La Ligue, Lille, France
- Université Lille-Nord de France, Lille, France
- Institut Pasteur de Lille, F-59019 Lille, France
- * E-mail:
| |
Collapse
|
27
|
Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 2010; 116:3645-52. [PMID: 20696945 DOI: 10.1182/blood-2009-12-261131] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We have studied the effect of a 13-bp deletion in the promoter of the von Willebrand factor (VWF) gene in a patient with type 1 von Willebrand disease. The index case has a VWF:Ag of 0.49 IU/mL and is heterozygous for the deletion. The deletion is located 48 bp 5' of the transcription start site, and in silico analysis, electrophoretic mobility shift assays, and chromatin immunoprecipitation studies all predict aberrant binding of Ets transcription factors to the site of the deletion. Transduction of reporter gene constructs into blood outgrowth endothelial cells showed a 50.5% reduction in expression with the mutant promoter (n = 16, P < .001). A similar 40% loss of transactivation was documented in transduced HepG2 cells. A similar marked reduction of transgene expression was shown in the livers of mice injected with the mutant promoter construct (n = 8, P = .003). Finally, in studies of BOEC mRNA, the index case showed a 4.6-fold reduction of expression of the VWF transcript associated with the deletion mutation. These studies show that the 13-bp deletion mutation alters the binding of Ets (and possibly GATA) proteins to the VWF promoter and significantly reduces VWF expression, thus playing a central pathogenic role in the type 1 von Willebrand disease phenotype in the index case.
Collapse
|
28
|
Nassiri M, Liu J, Kulak S, Uwiera RRE, Aird WC, Ballermann BJ, Jahroudi N. Repressors NFI and NFY participate in organ-specific regulation of von Willebrand factor promoter activity in transgenic mice. Arterioscler Thromb Vasc Biol 2010; 30:1423-9. [PMID: 20431063 DOI: 10.1161/atvbaha.110.206680] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To determine the role of repressors in cell type and organ-specific activation of von Willebrand factor (VWF) promoter sequences -487 to 247 in vivo. METHODS AND RESULTS Activation patterns of wild-type and mutant VWF promoters (sequences -487 to 247) containing mutations in repressors nuclear factor-I (NFI)- and nuclear factor Y (NFY)-binding sites were analyzed in transgenic mice. Mutation of the NFI-binding site activated the promoter in heart and lung endothelial cells, whereas mutation of the NFY-binding site activated the promoter in kidney vasculature. Immunofluorescence analyses showed that NFIB was predominant in heart and lung endothelial cells, whereas NFIX was predominantly detected in kidney endothelial cell nuclei. By using chromatin immunoprecipitation, we demonstrated that the distal lung-specific enhancer (containing a YY1 site) of the VWF gene is brought in proximity to the NFI binding site. CONCLUSIONS The NFI and NFY repressors contribute differentially to organ-specific regulation of the VWF promoter, and the organ-specific action of NFI may reflect its organ-specific isoform distribution. In addition, the lung-specific enhancer region of the endogenous VWF gene may inhibit NFI repressor function through chromatin looping, which can approximate the 2 regions.
Collapse
Affiliation(s)
- Marjan Nassiri
- Department of Medicine, University of Alberta, Edmonton, AL, Canada
| | | | | | | | | | | | | |
Collapse
|
29
|
Liu J, Kanki Y, Okada Y, Jin E, Yano K, Shih SC, Minami T, Aird WC. A +220 GATA motif mediates basal but not endotoxin-repressible expression of the von Willebrand factor promoter in Hprt-targeted transgenic mice. J Thromb Haemost 2009; 7:1384-92. [PMID: 19496923 PMCID: PMC5303625 DOI: 10.1111/j.1538-7836.2009.03501.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND The von Willebrand factor (VWF) gene is a marker for spatial and temporal heterogeneity of the endothelium. A GATA motif at +220 has been implicated in basal VWF expression in vitro. Other studies have shown that GATA3 and VWF are transcriptionally downregulated in response to inflammatory mediators. OBJECTIVES Our goal was to determine the importance of the +220 GATA motif in mediating expression of VWF promoter in vivo, and to elucidate whether the GATA element plays a role in spatial and/or temporal regulation of VWF expression. METHODS ChIP and electrophoretic mobility shift assays were carried out in human umbilical vein endothelial cells (HUVEC). Reporter gene constructs containing 3.6 kb of the human VWF promoter with and without a mutation of the +220 GATA element were transfected into cultured endothelial cells or targeted to the Hprt locus of mice. The Hprt-targeted mice were subjected to endotoxemia. RESULTS In protein-DNA binding assays, the +220 GATA motif bound GATA-2, -3 and -6. Mutation of the GATA site resulted in reduced basal promoter activity in HUVEC. When targeted to the Hprt locus of mice, the GATA mutation resulted in a significant, proportionate reduction of promoter activity in LacZ expressing vascular beds. Systemic administration of lipopolysaccharide (LPS) resulted in a widespread reduction in VWF mRNA expression and promoter activity. LPS-mediated repression of the VWF promoter was unaffected by the GATA mutation. CONCLUSIONS A region of the VWF promoter between -2182 and the end of the first intron contains information for LPS-mediated gene repression. The +220 GATA motif is important for basal, but not LPS-repressible expression of the VWF gene.
Collapse
Affiliation(s)
- J Liu
- The Center for Vascular Biology Research and Division of Molecular and Vascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Le Bras A, Soncin F. [Genes that make the endothelial identity]. JOURNAL DE LA SOCIETE DE BIOLOGIE 2009; 203:125-41. [PMID: 19527626 DOI: 10.1051/jbio/2009016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
The endothelium is a tissue with a distinct identity due to the specific expression of molecular markers by endothelial cells. Further, the endothelium displays a structural heterogeneity illustrated by the expression of specific markers in arteries and in veins. Here, we present a review of the transcriptional and epigenetic mechanisms regulating the expression of the main markers of endothelial cells in man and mouse, demonstrating that there is no common and unique mechanism of specific expression of genes in these cells.
Collapse
Affiliation(s)
- Alexandra Le Bras
- Institut de Biologie de Lille, CNRS UMR8161, Equipe Labellisée Ligue Nationale contre le Cancer 2008, Université de Lille I, Université de Lille II, Institut Pasteur de Lille, 1, rue Calmette, 59021 Lille Cedex, France
| | | |
Collapse
|
31
|
Abstract
The transcription factor GATA-1 participates in programming the differentiation of multiple hematopoietic lineages. In megakaryopoiesis, loss of GATA-1 function produces complex developmental abnormalities and underlies the pathogenesis of megakaryocytic leukemia in Down syndrome. Its distinct functions in megakaryocyte and erythroid maturation remain incompletely understood. In this study, we identified functional and physical interaction of GATA-1 with components of the positive transcriptional elongation factor P-TEFb, a complex containing cyclin T1 and the cyclin-dependent kinase 9 (Cdk9). Megakaryocytic induction was associated with dynamic changes in endogenous P-TEFb composition, including recruitment of GATA-1 and dissociation of HEXIM1, a Cdk9 inhibitor. shRNA knockdowns and pharmacologic inhibition both confirmed contribution of Cdk9 activity to megakaryocytic differentiation. In mice with megakaryocytic GATA-1 deficiency, Cdk9 inhibition produced a fulminant but reversible megakaryoblastic disorder reminiscent of the transient myeloproliferative disorder of Down syndrome. P-TEFb has previously been implicated in promoting elongation of paused RNA polymerase II and in programming hypertrophic differentiation of cardiomyocytes. Our results offer evidence for P-TEFb cross-talk with GATA-1 in megakaryocytic differentiation, a program with parallels to cardiomyocyte hypertrophy.
Collapse
|
32
|
Hough C, Cameron CL, Notley CRP, Brown C, O'Brien L, Keightley AM, Berber E, Lillicrap D. Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter. J Thromb Haemost 2008; 6:1183-90. [PMID: 18485092 DOI: 10.1111/j.1538-7836.2008.03011.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Plasma von Willebrand factor (VWF) is mainly derived from endothelial cells, cells that express a large repertoire of genes that are transcriptionally regulated by fluid shear stress. Endothelial VWF expression is not uniform throughout the vasculature, and levels are increased at regions associated with disturbed blood flow and steep gradients of shear stress. It is, however, unknown whether shear stress influences the regulation of VWF gene expression. OBJECTIVES Our objective was to evaluate the effect of shear stress on endogenous endothelial VWF mRNA expression and VWF promoter (-2722 to -1224) activity and to determine whether genetic elements modulate this flow-induced expression. METHODS A parallel plate flow chamber was used to expose endothelial cells to a shear level of 15 dynes cm(-2) for 24 or 6 h. VWF mRNA expression was analyzed. Various VWF promoter constructs that each contain either SNP haplotypes 1 or 2 and either a 17-GT or a 23-GT repeat element were transfected into endothelial cells, and flow-induced promoter activation was assessed. RESULTS When endothelial cells were exposed to shear stress, endogenous VWF mRNA expression increased 1.84-fold and average VWF promoter activity was enhanced 3.4-fold. Single nucleotide polymorphisms at -2708 and -2525, and the shear stress-response element at -1585, are not responsible for the shear stress-induced increase. Rather a GT repeat element at -2124 mediates the increase in activity, and the length of this polymorphic repeat element influences the magnitude of induction. CONCLUSIONS Shear stress enhances VWF promoter activity and a polymorphic GT repeat element mediates the stress-induced transactivation.
Collapse
Affiliation(s)
- C Hough
- Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, ON, Canada
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Kleinschmidt AM, Nassiri M, Stitt MS, Wasserloos K, Watkins SC, Pitt BR, Jahroudi N. Sequences in intron 51 of the von Willebrand factor gene target promoter activation to a subset of lung endothelial cells in transgenic mice. J Biol Chem 2007; 283:2741-50. [PMID: 18048367 DOI: 10.1074/jbc.m705466200] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In vivo analyses of the VWF promoter previously demonstrated that a fragment spanning sequences -487 to +247 targets promoter activation to brain vascular endothelial cells, whereas a longer fragment including 2182 bp of the 5'-flanking sequences, the first exon, and the first intron activated expression in endothelial cells of the heart and muscles as well as the brain of transgenic mice. These results suggested that additional VWF gene sequences were required for expression in other vascular endothelial cells in vivo. We have now identified a region within intron 51 of the VWF gene that is DNase I-hypersensitive (HSS) specifically in non-endothelial cells and interacts with endothelial and non-endothelial specific complexes that contain YY1. We demonstrate that beta-actin is associated with YY1 specifically in the nucleus of non-endothelial cells and is a component of the nuclear protein complexes that interact with the DNase I-hypersensitive region. In vitro transfection analyses demonstrated that HSS sequences containing this YY1-binding site do not significantly affect VWF promoter activity. However, in vivo analyses demonstrated that addition of these sequences to the VWF promoter (-487 to +247) results in promoter activation in lung and brain vascular endothelial cells. These results demonstrate that the HSS sequences in intron 51 of the VWF gene contain cis-acting elements that are necessary for the VWF gene transcription in a subset of lung endothelial cells in vivo.
Collapse
|
34
|
In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer. Gene Ther 2007; 15:340-6. [PMID: 17989704 DOI: 10.1038/sj.gt.3303058] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Increasing the level and duration of transgene expression and restricting expression to vascular cells are important goals for clinically useful gene therapy vectors. We evaluated several promoters, enhancers and introns in endothelial, smooth muscle and liver cells in tissue culture and in vivo, comparing local delivery to the carotid artery with intravenous delivery to the liver. A 1800-bp fragment of the oxidized LDL receptor (LOX-1) promoter showed highest in vivo activity in the carotid artery, achieving 39% the activity of the reference cytomegalovirus promoter, with 188-fold greater specificity for carotid artery over liver. An enhancer from the Tie2 gene in combination with the intracellular adhesion molecule-2 promoter improved endothelial specificity of plasmid vectors, increased the expression from adenoviral vectors in cultured endothelial cells and doubled the specificity for carotid artery over liver in vivo. Adding a short intron to expression cassettes increased expression in both endothelial and smooth muscle cells in vitro; however, the eNOS enhancer failed to consistently increase the expression or endothelial specificity of the vector. In conclusion, elements from the LOX-1 promoter and Tie2 enhancer together with an intron can be used to improve vectors for vascular gene transfer.
Collapse
|
35
|
Peng Y, Stewart D, Li W, Hawkins M, Kulak S, Ballermann B, Jahroudi N. Irradiation modulates association of NF-Y with histone-modifying cofactors PCAF and HDAC. Oncogene 2007; 26:7576-83. [PMID: 17599060 DOI: 10.1038/sj.onc.1210565] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Post-irradiation complications including thrombus formation result from increased procoagulant activity of vascular endothelial cells and elevated levels of von Willebrand factor (VWF) contribute to this process. We have previously demonstrated that irradiation induction of the VWF is mediated through interaction of NF-Y transcription factor with its cognate binding site in the VWF promoter. We have also demonstrated that irradiation increases the association of NF-Y with histone acetyltransferase p300/CBP-associated factor (PCAF). We now report that irradiation decreases the association of NF-Y with histone deacetylase 1 (HDAC1). We demonstrate that irradiation-induced changes in association of NF-Y with HDAC1 and PCAF lead to increased PCAF recruitment to the VWF promoter, increased association of acetylated histone H4 with the VWF promoter and subsequently increased transcription. We also demonstrate that this process is correlated to dephosphorylation of HDAC1 and is inhibited by calyculin A, an inhibitor of protein phosphatase1.
Collapse
Affiliation(s)
- Y Peng
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Welikson RE, Kaestner S, Evans AM, Hauschka SD. Embryonic cardiomyocyte expression of endothelial genes. Dev Dyn 2007; 236:2512-22. [PMID: 17685474 DOI: 10.1002/dvdy.21276] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Vertebrate precardiac mesoderm contains cells destined to become cardiomyocyte or endothelial cells. To determine the stability of these phenotypes freshly isolated embryonic day (E) 2.5-E6 chicken hearts were immunostained for myosin heavy chain (MyHC) to identify cardiomyocytes, and von Willebrand factor (vWF) and Flk-1 to identify endothelial cells. At E2.5-E3, 90% of cells express only MyHC and 6% express only vWF/Flk-1. However, 2% MyHC+ cells in E2.5-E3 hearts and 0.3% in E4-E6 hearts, also express vWF/Flk-1; and when cultured 3 days, >40% of the MyHC+ cells express vWF/Flk-1, but they do not express Vezf1, vascular endothelial cadherin, or Tie2. Thus, only a subset of endothelial genes are induced in cultured cardiomyocytes. While the subsequent developmental fate of embryonic heart cells exhibiting a vWF+/MyHC+ phenotype is unknown, analysis of this phenotype may provide information pertinent to mechanisms of cell phenotype stability, cellular transdifferentiation, and induction of stable cell types from embryonic stem cells.
Collapse
Affiliation(s)
- Robert E Welikson
- Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA
| | | | | | | |
Collapse
|
37
|
Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, Crosslin DR, Hale AB, Nelson S, Crossman DC, Granger CB, Haines JL, Jones CJH, Vance JM, Goldschmidt-Clermont PJ, Kraus WE, Hauser ER, Gregory SG. GATA2 is associated with familial early-onset coronary artery disease. PLoS Genet 2006; 2:e139. [PMID: 16934006 PMCID: PMC1557786 DOI: 10.1371/journal.pgen.0020139] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2006] [Accepted: 07/20/2006] [Indexed: 12/26/2022] Open
Abstract
The transcription factor GATA2 plays an essential role in the establishment and maintenance of adult hematopoiesis. It is expressed in hematopoietic stem cells, as well as the cells that make up the aortic vasculature, namely aortic endothelial cells and smooth muscle cells. We have shown that GATA2 expression is predictive of location within the thoracic aorta; location is suggested to be a surrogate for disease susceptibility. The GATA2 gene maps beneath the Chromosome 3q linkage peak from our family-based sample set (GENECARD) study of early-onset coronary artery disease. Given these observations, we investigated the relationship of several known and novel polymorphisms within GATA2 to coronary artery disease. We identified five single nucleotide polymorphisms that were significantly associated with early-onset coronary artery disease in GENECARD. These results were validated by identifying significant association of two of these single nucleotide polymorphisms in an independent case-control sample set that was phenotypically similar to the GENECARD families. These observations identify GATA2 as a novel susceptibility gene for coronary artery disease and suggest that the study of this transcription factor and its downstream targets may uncover a regulatory network important for coronary artery disease inheritance. Coronary artery disease (CAD) is the most common form of heart disease in the Western world and is one of the leading causes of death in the United States. CAD is inherited and is a complex genetic disease because it results from changes to multiple genes acting in concert with one another and the environment. The authors locate CAD susceptibility genes by convergence of techniques and identify variation within a gene of interest in an early-onset CAD population. If a specific variant is found more often in affected individuals or families than in controls, this can suggest that this gene variant is associated with disease. The authors have identified a gene, GATA2, which is located in a genomic region suspected to contain genes for CAD and displays expression patterns predictive of location of disease within human donor aortas. They have identified several GATA2 variants that segregate with CAD in a family-based early-onset CAD population and have further validated two of these associations in a separate young case-control sample affected with CAD. These data imply that the transcription factor GATA2 may play a role in CAD susceptibility and suggest that the study of GATA2 targets may uncover a set of GATA2-regulated genes important to CAD inheritance.
Collapse
Affiliation(s)
- Jessica J Connelly
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Tianyuan Wang
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Julie E Cox
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Carol Haynes
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Liyong Wang
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Svati H Shah
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
- Department of Medicine and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, United States
| | - David R Crosslin
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - A. Brent Hale
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Sarah Nelson
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - David C Crossman
- Cardiovascular Research Group, Northern General Hospital, University of Sheffield, Sheffield, United Kingdom
| | - Christopher B Granger
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Jonathan L Haines
- Center for Human Genetics Research and Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States
| | | | - Jeffery M Vance
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | | | - William E Kraus
- Department of Medicine and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, United States
| | - Elizabeth R Hauser
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
| | - Simon G Gregory
- Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
38
|
Sharifi BG, Zeng Z, Wang L, Song L, Chen H, Qin M, Sierra-Honigmann MR, Wachsmann-Hogiu S, Shah PK. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26:1273-80. [PMID: 16614316 PMCID: PMC3579570 DOI: 10.1161/01.atv.0000222017.05085.8e] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE Pleiotrophin (PTN) is a cytokine that is expressed by monocytes/macrophages in ischemic tissues and that promotes neovascularization, presumably by stimulating proliferation of local endothelial cells. However, the effect of PTN on monocytes/macrophages remains unknown. We investigated the role of PTN in regulating the phenotype of monocytes/macrophages. METHODS AND RESULTS RT-PCR, real-time PCR, and fluorescence-activated cell sorter analysis revealed that the expression of PTN by monocytic cells led to a downregulation of CD68, c-fms, and CD14 monocytic cell markers and an upregulation of FLK-1, Tie-2, vascular endothelial-cadherin, platelet endothelial cell adhesion molecule-1, endothelial NO synthase, von Willebrand factor, CD34, GATA-2, and GATA-3 endothelial cell markers. Fibrin gel assays showed that the treatment of mouse and human monocytic cells with PTN led to the formation of tube-like structures. In vivo studies showed that PTN-expressing monocytic cells incorporated into the blood vessels of the quail chorioallantoic membrane. The intracardial injection of PTN-expressing monocytic cells into chicken embryos showed that cells integrated only into the developing vasculature. Finally, the injection of PTN-expressing monocytes into a murine ischemic hindlimb model significantly improved perfusion of the ischemic tissue. CONCLUSIONS PTN expression by monocytes/macrophages led to a downregulation of their monocytic cell markers and an upregulation of endothelial cell characteristics, thus inducing the transdifferentiation of monocytes into functional endothelial cells.
Collapse
Affiliation(s)
- Behrooz G Sharifi
- Atherosclerosis Research Center, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Martin TA, Watkins G, Lane J, Jiang WG. Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 2005; 46:422-30. [PMID: 15810954 DOI: 10.1111/j.1365-2559.2005.02104.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIMS Vascular endothelial (VE)-cadherin, also known as cadherin-5 and CD144, is an adhesion molecule uniquely expressed in endothelial cells. We hypothesized that VE-cadherin may be a useful marker for assessing microvessels and angiogenesis in human breast cancer and sought to determine whether a correlation exists between levels of VE-cadherin, angiogenic markers factor VIII and platelet endothelial cell adhesion molecule (PECAM)-1 and patient outcome in breast cancer. METHODS AND RESULTS Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed. RNA was reverse transcribed and analysed by quantitative polymerase chain reaction (Q-PCR). VE-cadherin immunostaining showed a significant difference in microvessel number in tumour compared with background. There was no significant difference in the number of microvessels stained with PECAM-1 or factor VIII; there was increased staining of other structures within the sample and higher general background staining. Q-PCR revealed elevated levels of VE-cadherin and PECAM-1 in tumour samples compared with background tissue and in patients with a poor prognosis, as determined by the Nottingham Prognostic Index. There was no difference in levels with factor VIII. Both VE-cadherin and PECAM-1 had significantly reduced expression in lobular compared with ductal carcinomas: there was no difference with factor VIII. CONCLUSION Higher levels of angiogenic marker molecules in breast cancer may have an association with poor prognosis in patients. Moreover, VE-cadherin appears to be a preferable marker for such analysis.
Collapse
Affiliation(s)
- T A Martin
- Metastasis Research Group, University Department of Surgery, University of Wales College of Medicine, Cardiff, UK.
| | | | | | | |
Collapse
|
40
|
Hough C, Cuthbert CD, Notley C, Brown C, Hegadorn C, Berber E, Lillicrap D. Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor. Blood 2004; 105:1531-9. [PMID: 15498853 DOI: 10.1182/blood-2002-10-3093] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Mechanisms of tissue-restricted patterns of von Willebrand factor (VWF) expression involve activators and repressors that limit expression to endothelial cells and megakaryocytes. The relative transcriptional activity of the proximal VWF promoter was assessed in VWF-producing and -nonproducing cells, and promoter activity was highest in endothelial cells followed by megakaryocytes. Only basal VWF promoter activity was seen in nonendothelial cells. Here we identify a negative response element located at nucleotides (nts) +96/+105 and demonstrate, using chromatin immunoprecipitation (ChIP) analysis, that in vivo this sequence interacts with the E4BP4 transcriptional repressor. Differences in size and relative abundance of nuclear E4BP4 were observed. In HepG2 cells, low levels of larger forms of E4BP4 are present that directly interact with the negative response element. In VWF-expressing cells, high levels of smaller forms predominate with no evidence of direct DNA binding. However, in endothelial cells, mutation of the VWF E4BP4 binding motif not only restores but also further elevates VWF promoter activity, suggesting that E4BP4 may be part of a coordinated binding complex. These observations implicate this binding motif in repressing both activated and basal levels of VWF transcription by different cell type-specific mechanisms, and support the hypothesis that E4BP4 sequesters negative regulators of transcription, thereby enhancing activated gene expression.
Collapse
Affiliation(s)
- Christine Hough
- The Department of Pathology and Molecular Medicine, Richardson Laboratories, Queen's University, Kingston, ON, Canada, K7L 3N6
| | | | | | | | | | | | | |
Collapse
|
41
|
Wang X, Peng Y, Ma Y, Jahroudi N. Histone H1–like protein participates in endothelial cell–specific activation of the von Willebrand factor promoter. Blood 2004; 104:1725-32. [PMID: 15150074 DOI: 10.1182/blood-2004-01-0082] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AbstractA region of the von Willebrand factor (VWF) promoter has been identified that is necessary to confer endothelial cell-specific activation to the VWF promoter. This region spans sequences +155 to +247 and contains binding sites for GATA6 and NFY transcription factors. To identify potential DNA binding transcription factors that directly interact with these sequences in an endothelial-specific manner, we have performed extensive gel mobility assays with use of 7 overlapping DNA probes that collectively span this entire region. An endothelial-specific protein DNA complex was formed with an oligonucleotide that corresponded to sequences +155 to +184 of the VWF gene. Mutation analysis identified a 6-nucleotide element corresponding to sequences +164 to +169 as the core-binding region for the formation of this complex. Transfection analysis demonstrated that the mutation, which abolished DNA-protein interaction, resulted in significant inhibition of the VWF promoter activity. DNA pull-down analysis, mass spectrometry, and Western blot analysis demonstrated that a 32-kDa polypeptide with homology to histone H1 constituted the endothelial-specific DNA binding protein, or a DNA binding subunit of this protein complex. On the basis of these results, we hypothesize that an H1-like protein functions as an endothelial cell-specific transcriptional activator of the VWF promoter. (Blood. 2004;104: 1725-1732)
Collapse
Affiliation(s)
- Xinyu Wang
- Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA
| | | | | | | |
Collapse
|
42
|
Seki T, Hong KH, Yun J, Kim SJ, Oh SP. Isolation of a Regulatory Region of Activin Receptor-Like Kinase 1 Gene Sufficient for Arterial Endothelium-Specific Expression. Circ Res 2004; 94:e72-7. [PMID: 15059937 DOI: 10.1161/01.res.0000127048.81744.31] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Activin receptor-like kinase 1 (Acvrl1; Alk1) is a type I receptor for transforming growth factor-beta (TGF-beta). ALK1 plays a pivotal role in vascular development and is involved in the development of hereditary hemorrhagic telangiectasia 2 (HHT2), a dominantly inherited vascular disorder, and pulmonary hypertension. We have previously shown that Alk1 is expressed predominantly in arterial endothelial cells (ECs). Despite recent discoveries of a number of artery-specific genes, the regulatory elements of these genes have not been characterized. To investigate the cis-acting elements essential for the artery-specific Alk1 expression, we have generated a series of transgenic constructs with various lengths and regions of Alk1 genomic fragments connected to a LacZ reporter gene, and analyzed the reporter gene expression in transgenic mice. We found that a 9.2-kb genomic fragment, which includes 2.7-kb promoter region and the entire intron 2, is sufficient to drive arterial endothelium-specific expression. The defined regulatory region, as well as the transgenic mouse lines, would be invaluable resources in studying the mechanisms underlying angiogenesis, arteriogenesis, and vascular disorders, such as HHT and pulmonary hypertension. The full text of this article is available online at http://circres.ahajournals.org.
Collapse
MESH Headings
- Activin Receptors, Type I/biosynthesis
- Activin Receptors, Type I/genetics
- Activin Receptors, Type I/physiology
- Activin Receptors, Type II
- Animals
- Arteries/cytology
- Arteries/embryology
- Arteries/growth & development
- Arteries/metabolism
- Binding Sites
- Consensus Sequence
- Endothelium, Vascular/metabolism
- Exons/genetics
- Female
- Gene Expression Regulation, Developmental
- Genes, Reporter
- Humans
- Introns/genetics
- Lac Operon
- Male
- Mice
- Mice, Transgenic
- Neovascularization, Physiologic/genetics
- Organ Specificity
- Promoter Regions, Genetic/genetics
- Regulatory Sequences, Nucleic Acid
- Sequence Alignment
- Sequence Homology
- Skin/injuries
- Species Specificity
- Transcription Factors/metabolism
- Wound Healing/genetics
Collapse
Affiliation(s)
- Tsugio Seki
- Department of Physiology and Functional Genomics, University of Florida,Gainesville, Fla 32610, USA
| | | | | | | | | |
Collapse
|
43
|
Minami T, Kuivenhoven JA, Evans V, Kodama T, Rosenberg RD, Aird WC. Ets motifs are necessary for endothelial cell-specific expression of a 723-bp Tie-2 promoter/enhancer in Hprt targeted transgenic mice. Arterioscler Thromb Vasc Biol 2003; 23:2041-7. [PMID: 12893685 DOI: 10.1161/01.atv.0000089326.63053.9a] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Tie-2 is an endothelial cell-specific receptor tyrosine kinase that is involved in the remodeling of blood vessels and angiogenesis. Our goal was to characterize Tie-2 promoter function as a means of providing insight into the mechanisms of endothelial cell-specific gene regulation. METHODS AND RESULTS When targeted to the Hprt locus of mice, a small Tie-2 promoter fragment (containing a 300-bp intronic enhancer coupled upstream to a 423-bp core promoter) (T-short) directed widespread endothelial cell expression in vivo. The T-short promoter contains 2 clusters of Ets sites, one in the first exon, the other in the intronic enhancer. In cultured endothelial cells, a combined mutation of the Ets motifs resulted in a significant reduction in promoter activity. Consistent with these results, the same Ets mutations resulted in a loss of detectable expression of the T-short promoter in all vascular beds with the notable exception of the brain. CONCLUSIONS These results suggest that the T-short promoter contains information for widespread expression in the vascular tree, Ets sites are necessary for in vivo promoter activity, and the shorter Tie-2 fragment may be useful as a tool to direct heterologous gene expression within the intact endothelium.
Collapse
Affiliation(s)
- Takashi Minami
- Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1 Komaba, Meguro Tokyo, 153-8904.
| | | | | | | | | | | |
Collapse
|
44
|
Chun TH, Itoh H, Subramanian L, Iñiguez-Lluhí JA, Nakao K. Modification of GATA-2 transcriptional activity in endothelial cells by the SUMO E3 ligase PIASy. Circ Res 2003; 92:1201-8. [PMID: 12750312 DOI: 10.1161/01.res.0000076893.70898.36] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
GATA sequences are required for the optimal expression of endothelial cell-specific genes, including endothelin-1 (ET-1). We have identified PIASy in a search for new GATA-2 interacting proteins that can regulate GATA-2-mediated endothelial gene expression. Notably, among the cell populations comprising vascular walls, PIASy mRNA is selectively expressed in endothelial cells, and its expression can be regulated by angiogenic growth factors. We show that GATA-2 is covalently modified by small ubiquitin-like modifier (SUMO)-1 and -2 and that PIASy, through its E3 SUMO ligase activity, preferentially enhances the conjugation of SUMO-2 to GATA-2. Through a functional analysis, we demonstrate that PIASy potently suppresses the activity of the GATA-2-dependent human ET-1 promoter in endothelial cells. The suppressive effect of PIASy requires the GATA-binding site in the ET-1 promoter and depends on its interaction with GATA-2, which requires both N-terminal (amino acids 1-183) and C-terminal (amino acids 414-510) sequences in PIASy. We conclude that PIASy enhances the conjugation of SUMO-2 to GATA-2 and that the interaction of PIASy with GATA-2 can modulate GATA-mediated ET-1 transcription activity in endothelial cells through a RING-like domain-independent mechanism.
Collapse
Affiliation(s)
- Tae-Hwa Chun
- Department of Medicine and Clinical Science, University Graduate School of Medicine, Kyoto, Japan.
| | | | | | | | | |
Collapse
|
45
|
Okita K, Nobuhisa I, Takizawa M, Ueno M, Kimura N, Taga T. Genomic organization and characterization of the mouse ELYS gene. Biochem Biophys Res Commun 2003; 305:327-32. [PMID: 12745078 DOI: 10.1016/s0006-291x(03)00772-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Differentiation of hematopoietic stem cells into blood cells is controlled by several transcription factors. Recently, we identified a putative transcription factor, ELYS (for embryonic large molecule derived from yolk sac), using a subtraction strategy. During mouse embryogenesis, ELYS transcripts were predominantly expressed in hematopoietic tissues, such as the yolk sac, aorta-gonad-mesonephros (AGM), and liver. Here, we report the cloning and characterization of the mouse ELYS gene. The ELYS gene spanned approximately 60kb encoding 36 exons, and was assigned between D1Mit315 and D1Mit458 markers in chromosome 1. The transcription initiation site was identified as the G residue located 670bp upstream of the translation start codon. A region downstream of the transcriptional start site contributed to high promoter activity. This region contained potential DNA elements for transcription factors such as GATA-1, -2, -3, heat shock factor (HSF) 2, and NF-kappaB, which are known to play important roles in hematopoietic events.
Collapse
Affiliation(s)
- Keisuke Okita
- Department of Cell Fate Modulation, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto 860-0811, Japan
| | | | | | | | | | | |
Collapse
|
46
|
Perkins KJ, Davies KE. Ets, Ap-1 and GATA factor families regulate the utrophin B promoter: potential regulatory mechanisms for endothelial-specific expression. FEBS Lett 2003; 538:168-72. [PMID: 12633873 DOI: 10.1016/s0014-5793(03)00175-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Duchenne muscular dystrophy is caused by dystrophin deficiency, which can be prevented in the mdx mouse model by over-expression of an autosomal homologue, utrophin. Utrophin has two characterised full-length promoters, A and B. No data are available on the transcriptional regulation of B utrophin, which has been recently localised to the endothelium. Similar to characterised endothelial promoters, Ets and Ap-1 individually trans-activate the human B core promoter. Synergistic activation by GATA-2 and c-jun to the order of 20-fold was observed.
Collapse
Affiliation(s)
- Kelly J Perkins
- Department of Human Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
| | | |
Collapse
|
47
|
Peng Y, Jahroudi N. The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem 2003; 278:8385-94. [PMID: 12511565 DOI: 10.1074/jbc.m213156200] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Human von Willebrand factor (VWF) gene sequences +155 to +247 contain cis-acting elements that contribute toward endothelial specific activation of the VWF promoter. Analyses of this region demonstrated the presence of a GATA-binding site that is necessary for the promoter activation in endothelial cells. We have reported recently the presence of a novel NFY-binding sequence in this region that does not conform to the consensus NFY-binding sequence CCAAT. NFY was shown to function as a repressor of the VWF promoter through interaction with this novel binding site. Here we report that the NFY interacts with histone deacetylases (HDACs) in a cell type-specific manner and recruits them to the VWF promoter to inhibit the promoter activity in non-endothelial cells. Analyses of the acetylation status of histones in the chromatin region containing the VWF promoter sequences demonstrated that these sequences are associated with acetylated histone H4 specifically in endothelial cells. It was also demonstrated that HDACs are specifically recruited to the same chromatin region in non-endothelial cells. We also demonstrated that GATA6 is the GATA family member that interacts with the VWF promoter and that GATA6 is associated with NFY specifically in non-endothelial cells. We propose that NFY recruits HDACs to the VWF promoter, which may result in deacetylation of GATA6 as well as of histones in non-endothelial cells, thus leading to promoter inactivation. In endothelial cells, however, association of HDACs, NFY, and GATA6 is interrupted potentially through endothelial cell-specific signaling/mechanism, thus favoring the balance toward acetylation and activation of the VWF promoter.
Collapse
Affiliation(s)
- Yiwen Peng
- Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
| | | |
Collapse
|
48
|
Nicklin SA, Baker AH. Development of targeted viral vectors for cardiovascular gene therapy. GENETIC ENGINEERING 2003; 25:15-49. [PMID: 15260232 DOI: 10.1007/978-1-4615-0073-5_2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Affiliation(s)
- Stuart A Nicklin
- British Heart Foundation Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK
| | | |
Collapse
|
49
|
Laprise MH, Grondin F, Cayer P, McDonald PP, Dubois CM. Furin gene (fur) regulation in differentiating human megakaryoblastic Dami cells: involvement of the proximal GATA recognition motif in the P1 promoter and impact on the maturation of furin substrates. Blood 2002; 100:3578-87. [PMID: 12411321 DOI: 10.1182/blood.v100.10.3578] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The convertase furin is involved in the maturation of key growth/aggregation mediators synthesized by the platelet producers, megakaryocytes, but the regulation of furin in these cells remains unknown. Computer-assisted search of the furin promoter sequence revealed multiple potential binding motifs for GATA-1, suggesting that furin is expressed and regulated in these cells. Using megakaryoblastic Dami cells, we observed that fur mRNA expression increased gradually on phorbol 12-myristate 13-acetate-induced differentiation, reaching maximum levels (8.3-fold increase) at 10 days. Transient transfections with P1, P1A, or P1B fur-LUC-promoter constructs revealed that in Dami cells, the P1 promoter is the strongest and the most sensitive to forced expression of GATA-1. Coexpression of GATA-1 and its comodulator, Friend of GATA-1 (FOG-1), resulted in a cooperative increase in P1 activity. Deletion analysis indicated that important GATA-1-regulated sequences are located in the most proximal region of the P1 promoter. Further analysis revealed 2 potential GATA-binding motifs at positions -66 and +62. Point mutation of each of the 2 motifs indicated that the intactness of the first GATA site is required for full basal and GATA-1-stimulated promoter activity. Finally, the inhibition of furin activity through gene transfer of the inhibitor alpha1-AT-PDX led to a block in maturation of the furin substrates transforming growth factor-beta1 and platelet-derived growth factor. Taken together, these results indicate that the most proximal GATA element in the P1 promoter is needed for fur gene expression in megakaryoblastic cells. They also suggest that proper regulation of the fur gene in megakaryocytes has an impact on the activation of furin substrates involved in megakaryocyte maturation and platelet functions.
Collapse
Affiliation(s)
- Marie-Hélène Laprise
- Immunology Division, Department of Pediatrics, Faculty of Medicine, University of Sherbrooke, Québec, PQ, Canada
| | | | | | | | | |
Collapse
|
50
|
Peng Y, Jahroudi N. The NFY transcription factor functions as a repressor and activator of the von Willebrand factor promoter. Blood 2002; 99:2408-17. [PMID: 11895773 DOI: 10.1182/blood.v99.7.2408] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Human von Willebrand factor (VWF) gene sequences -487 to +247 function as an endothelial-specific promoter in vitro. Analysis of the activation mechanism of the VWF promoter has resulted in the identification of a number of cis-acting elements and trans-acting factors that regulate its activity. The GATA and Ets transcription factors were shown to function as activators of transcription, whereas NF1 and Oct1 were shown to repress transcription. We have reported the presence of another repressor element in exon 1 that interacted with a protein complex designated "R." In the absence of NF1 binding, inhibition of this interaction resulted in promoter activation in nonendothelial cells. We have now identified the "R" protein complex as the NFY transcription factor. Using DNA methylation interference assay and base substitution mutation analysis, we show that NFY interacts with a novel DNA sequence corresponding to nucleotides +226 to +234 in the VWF promoter that does not conform to the consensus NFY binding sequence CCAAT. The VWF gene does contain a CCAAT element that is located downstream of the TATA box and we show that the NFY factor also interacts with this CCAAT element. Using antibodies specific against the A, B, and C subunits of NFY, we demonstrate that the NFY complexes interacting with the CCAAT sequence have a composition similar to that of the repressor binding to the first exon sequences. The results of mutation analysis and transfection studies demonstrated that the interaction of NFY with the upstream CCAAT element is required for VWF promoter activation. Based on these results, we hypothesize that NFY can function both as a repressor and activator of transcription and its function may be modulated through its DNA binding sequences.
Collapse
Affiliation(s)
- Yiwen Peng
- Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA
| | | |
Collapse
|